Join Webinar

Business News

Merck to buy Peloton for $1.05 billion

Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company’s renal cancer drug candidate.

The company’s lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.

Peloton shareholders will be eligible to receive a further $1.15 billion on achieving certain milestones.

The company had been looking to go public and gave a pricing range of $15 to $17 per share for its initial public offering last week. Credit Suisse acted as financial adviser for Merck and Covington & Burling LLP as its legal adviser.
  • Merck & Co Inc
  • Buy
  • Peloton Therapeutics
  • Cancer Drug Candidate
  • PT2977
JSRS Banner
JSRS Banner